Oncology - Page 1

OncoMed initiates Phase Ib/II small cell lung cancer trial of OMP-59R5
Wednesday, May 15, 2013 OncoMed Pharmaceuticals has initiated a Phase Ib/II trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer...

Mirna initiates Phase I trial of anti-cancer drug MRX34
Wednesday, May 15, 2013 MicroRNA therapy developer Mirna Therapeutics has commenced a Phase I trial of anti-cancer drug...

MorphoSys commences patient dosing in Phase II study of lymphoma drug
Tuesday, May 14, 2013 MorphoSys has commenced patient dosing in a Phase II study of anti-CD19 antibody MOR208 for the treatment of non-Hodgkin's lymphoma...

Eli Lilly reports poor results from Phase III diffuse large B-cell lymphoma study
Monday, May 13, 2013 Eli Lilly and Company has announced that a Phase III study designed to evaluate enzastaurin as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL)...

Prometheus commences enrolment in Phase IV trial of Proleukin
Monday, May 13, 2013 Specialty pharmaceutical and diagnostic company Prometheus Laboratories has commenced enrolment in a multicentre Phase IV trial evaluating Proleukin (high-dose interleukin-2 (HD IL-2)), along...

La Jolla completes patient dosing in Phase I portion of GCS-100 clinical trial
Wednesday, May 08, 2013 La Jolla Pharmaceutical has treated the last patient in the Phase I (Part A) portion of its Phase I/II clinical trial of GCS-100 to treat chronic kidney disease...

Senesco commences third cohort of Phase Ib/IIa study for cancer therapy candidate SNS01-T
Tuesday, May 07, 2013 US-based Senesco has commenced the third cohort in its Phase Ib/IIa study for its lead therapeutic candidate SNS01-T, a therapy designed to selectively trigger apoptosis in B-cell cancers such...

OncoGenex to commence Phase II trial of OGX-427 in metastatic pancreatic cancer patients
Friday, May 03, 2013 OncoGenex has announced plans to begin a Phase II trial of OGX-427 in treatment-naive metastatic pancreatic cancer...

Genmab reports top-line results from Phase II CLL study of ofatumumab
Thursday, May 02, 2013 Genmab has reported top-line results from a Phase II study of ofatumumab combined with bendamustine in untreated and relapsed chronic lymphocytic leukemia...

GTx commences enobosarm Phase II metastatic breast cancer study
Wednesday, May 01, 2013 Biopharmaceutical company GTx is commencing a Phase II open-label study of selective androgen receptor modulator enobosarm (GTx-024), to treat estrogen receptor (ER) positive metastatic breast...

Merrimack completes enrolment in second cohort of lung cancer study
Tuesday, April 30, 2013 Merrimack Pharmaceuticals has completed patient enrolment in the second cohort of its MM-121 Phase II study in non-small cell lung cancer...

MorphoSys doses first patient in Phase II trial of MOR208 leukemia drug
Monday, April 29, 2013 MorphoSys has announced dosing of the first patient in its Phase II trial of MOR208 in patients with B-cell acute lymphoblastic leukemia...

BioInvent treats first patient in Phase II smoldering myeloma study of BI-505
Tuesday, April 23, 2013 Research-based pharmaceutical company BioInvent International has treated the first patient in a Phase II study of BI-505 in smoldering multiple...

BIND, AstraZeneca to jointly develop Accurin cancer nanomedicine
Tuesday, April 23, 2013 BIND Therapeutics and AstraZeneca have signed global development and commercialisation agreement for Accurin cancer...

Merrimack completes patient enrolment in one cohort of Phase 2 study into breast cancer agent
Tuesday, April 16, 2013 Biopharmaceutical company Merrimack Pharmaceuticals has completed patient enrolment in one group of a two-cohort randomised Phase 2 study of MM-121 in HER2-negative breast...

OncoGenex to begin Spruce clinical trial of OGX-427 cancer agent
Monday, April 15, 2013 Biopharmaceutical company OncoGenex is planning to begin the Spruce clinical trial, evaluating OGX-427 in combination with chemotherapy in patients with previously untreated advanced...

Sunshine anticancer compound demonstrates non-toxicity at high concentrations
Thursday, April 11, 2013 Pharmaceutical company Sunshine Biopharma's HMEC study has indicated the non-toxicity of anticancer compound Adva-27a to healthy tissue at high...

Astellas collaborates with Ambrx for antibody drug conjugates development
Monday, April 08, 2013 Astellas Pharma has collaborated with Ambrx for the discovery and development of next-generation antibody drug conjugates (ADCs) for...

Aragon doses first patient in Phase I breast cancer study of ARN-810
Friday, April 05, 2013 Aragon Pharmaceuticals has announced the dosing of the first patient in its Phase I study of ARN-810 in estrogen receptor-positive breast...

Axelar AXL-003 demonstrates efficacy in second line treatment of lung cancer patients
Tuesday, April 02, 2013 Swedish biotech company Axelar has reported preliminary interim results of its Phase II study indicating AXL-003's efficacy as a second-line treatment for patients with non-small cell lung...